# Melazyme

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/melazyme

- Industry: Biotechnology
- Headquarters: Salt Lake City, US
- Website: https://melazyme.com/
- Total disclosed funding: $2M
- Latest round: Seed (May 14, 2026)
- Investors on record: 3

## About

Melazyme Inc., based in the US, delivers customizable biotechnological solutions, with a primary emphasis on enzyme products tailored for various industrial applications, including agriculture, food processing, and pharmaceuticals.Established in 2025 and headquartered in Salt Lake City, US, Melazyme Inc. specializes in enzyme development for multiple sectors. The company was co-founded by Perumal Gandhi and Bonney Oommen, and in May 2026, the company raised USD 2 million in seed funding led by SeaX Ventures, with participation from Stellaris Venture Partners and Plug and Play. Melazyme specializes in innovative biotechnological solutions targeting various sectors, focusing on enzyme products designed for industrial applications. Their flagship offerings include proprietary enzymes engineered for agriculture, food processing, and pharmaceuticals, enhancing efficiency and sustainability in these industries. By addressing specific challenges such as crop yield improvement, food preservation, and pharmaceutical production optimization, Melazyme provides high-performance solutions tailored to its clients' needs. Their products cater to a diverse clientele, including agricultural producers, food manufacturers, and pharmaceutical companies, primarily in North America and Europe, reinforcing their commitment to quality and value across multiple sectors.Melazyme generates revenue through a structured business model that encompasses both B2B and direct-to-consumer transactions. The company operates on a partnership basis with its clients, supplying enzyme products under long-term contracts that facilitate consistent revenue flow. Transactions involve the sale of enzyme formulations, priced according to volume and application, ensuring competitive positioning within the market. Key offerings include specialized enzyme blends that cater to various industries' specific needs, reinforcing customer loyalty and repeat business. Their revenue structure supports sustainable growth by leveraging partnerships and strategic distribution channels to maximize market reach and client satisfaction.In May 2026, Melazyme Inc. secured USD 2.000 mn in Seed funding to accelerate enzyme optimization, expand its R&D team, and launch pilot programs with industrial partners. The company is actively developing new enzyme products aimed at enhancing industrial efficacy, with plans for release in the near term. Additionally, they are targeting expansion into new geographic markets, although specific regions have not been disclosed.

## Funding rounds

- Seed, May 14, 2026, $2M — Plug and Play, Stellaris Venture Partners, SeaX Ventures

## Investors

- Plug and Play (https://capitalatlas.ai/funds/plug-and-play) — Seed
- Stellaris Venture Partners (https://capitalatlas.ai/funds/stellaris-venture-partners) — Seed
- SeaX Ventures (https://capitalatlas.ai/funds/seax-ventures) — Seed